CSPC Pharmaceutical Group (HKG:1093) officially initiated two clinical trials in China, two Monday bourse filings showed.
The pharma company is testing SYS6052, a recombinant herpes zoster virus vaccine, and SYS6057, a recombinant respiratory syncytial virus vaccine.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments